Erscheint 12 Ausgaben pro Jahr
ISSN Druckformat: 1521-9437
ISSN Online: 1940-4344
Indexed in
A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. (Ling Zhi, Reishi Mushroom) Extract in Patients with Chronic Hepatitis В
ABSTRAKT
The polysaccharide fractions and triterpenes isolated from Ganoderma lucidum have shown protection effects on the liver in animal studies. This double-blind, randomised, and multicentered study aimed to evaluate the safety and effect of a G. lucidum extraction, Ganopoly, in chronic hepatitis B. Ninety patients with chronic hepatitis B, hepatitis В viral (HBV) DNA positivity, and aminotransferase elevation were included in this multicenter prospective randomized Phase I/II study. Patients were randomized to be given Ganopoly (n = 60) or placebo (n = 30) for 12 weeks, then followed up for 13 weeks. Effect of therapy on levels of HBV DNA and aminotransferase activities in serum and hepatitis В е antigen (HBeAg) status were investigated. There were 78 assessable patients who entered the trial for efficacy and safety; 13 of 52 (25%) patients receiving Ganopoly responded by reducing HBeAg and HBV DNA, compared to 1 of 26 (4%) in the control group (P < 0.05). Among those with serum aspartate aminotransferase (AST) values < 100 U/L (n = 29), 41% (12/29) responded, and among those with AST values > 100 U/L (n = 23), 65% (15/23) responded. Within the 6-month study period, 33% (17/ 52) of treated patients had normal aminotransferase (ALT) values, and 13% (7/52) had cleared hepatitis B surface antigen (HBsAg) from serum, whereas none of the controls had normal ALT values or had lost HBsAg. Eight of 60 patients in Ganopoly group and 4 of 30 in the controls were unable to be followed up due to loss or withdrawal. Our study indicates that Ganopoly is well tolerated and appears to be active against HBV in patients with chronic hepatitis B.
-
Gill Balraj Singh, Sharma Prateek, Kumar Raj, Kumar Sanjeev, Misconstrued versatility of Ganoderma lucidum: a key player in multi-targeted cellular signaling, Tumor Biology, 37, 3, 2016. Crossref
-
Sánchez Carmen, Bioactives from Mushroom and Their Application, in Food Bioactives, 2017. Crossref
-
Hsu Kai-Di, Cheng Kuan-Chen, From nutraceutical to clinical trial: frontiers in Ganoderma development, Applied Microbiology and Biotechnology, 102, 21, 2018. Crossref
-
Das Banani, De Biplab, Chetree Rishiraj, Mandal Subhash C., Medicinal Aspect of Mushrooms: A View Point, in Herbal Medicine in India, 2020. Crossref
-
Gupta Sachin, Summuna Baby, Gupta Moni, Annepu Sudheer K., Edible Mushrooms: Cultivation, Bioactive Molecules, and Health Benefits, in Bioactive Molecules in Food, 2019. Crossref
-
Gupta Sachin, Summuna Baby, Gupta Moni, Annepu Sudheer K., Edible Mushrooms: Cultivation, Bioactive Molecules, and Health Benefits, in Sweeteners, 2018. Crossref
-
Bolaniran Tolulope, Jamiu Abdullahi Temitope, Garuba Taofeeq, Wudil Alhassan Muhammad, Adeola Henry Ademola, Sabiu Saheed, An appraisal of the metabolites, pharmacological and biotechnological significance of edible mushrooms, Transactions of the Royal Society of South Africa, 76, 3, 2021. Crossref
-
Ahmad Rizwan, Riaz Muhammad, Khan Aslam, Aljamea Ahmed, Algheryafi Mohammad, Sewaket Deya, Alqathama Aljawharah, Ganoderma lucidum (Reishi) an edible mushroom; a comprehensive and critical review of its nutritional, cosmeceutical, mycochemical, pharmacological, clinical, and toxicological properties , Phytotherapy Research, 35, 11, 2021. Crossref
-
Oke M. A., Afolabi F. J., Oyeleke O. O., Kilani T. A., Adeosun A. R., Olanbiwoninu A. A., Adebayo E. A., Ganoderma lucidum: Unutilized natural medicine and promising future solution to emerging diseases in Africa, Frontiers in Pharmacology, 13, 2022. Crossref